Drug intelligence / Profile preview

AP362

Development stage: Preclinical
Lead developer: Arachos Pharma
Modality: Small Molecules
Administration: Oral

Overview

AP362 is a selective glucocorticoid receptor modulator (SGRM) with a novel profile of action. It is designed to retain the benefits of anti-inflammatory steroid medicines such as prednisolone while having fewer side effects. AP362 is a non-steroidal oral drug candidate that could potentially be taken as a once-daily tablet to control inflammatory diseases such as eczema, rheumatoid arthritis, and asthma.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on AP362.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP362.

Explore the full profile